catalyst
biosciences
announces
poster
presentation
annual
american
society
hematology
conference
south
san
francisco
globe
newswire
catalyst
biosciences
nasdaq
cbio
today
announced
trials
progress
poster
presentation
marzeptacog
alfa
activated
marzaa
company
subcutaneously
administered
engineered
coagulation
factor
viia
fviia
upcoming
annual
american
society
hematology
ash
meeting
held
virtually
december
poster
presentation
details
poster
title
crimson
study
phase
study
evaluate
efficacy
safety
subcutaneous
marzeptacog
alfa
activated
treatment
control
bleeding
episodes
subjects
hemophilia
hemophilia
b
inhibitors
presenting
author
linda
neuman
vice
president
clinical
development
catalyst
biosciences
date
time
sunday
december
pt
copy
presentation
materials
accessed
events
presentations
section
catalyst
website
day
presentation
marzaa
recombinant
factor
viia
variant
subcutaneously
administered
bypass
agent
development
treatment
hemophilia
b
inhibitors
rare
bleeding
disorders
including
factor
vii
deficiency
glanzmann
thrombasthenia
late
catalyst
biosciences
plans
dose
first
patient
crimson
phase
study
marzaa
treatment
episodic
bleeding
hemophilia
b
inhibitors
catalyst
biosciences
catalyst
research
clinical
development
biopharmaceutical
company
focused
addressing
unmet
medical
needs
rare
hematologic
disorders
protease
engineering
platform
generated
two
clinical
programs
hemophilia
research
program
engineering
subcutaneous
sq
complement
inhibitors
discovery
stage
factor
ix
gene
therapy
construct
cb
hemophilia
b
partnered
preclinical
development
program
biogen
dry
macular
degeneration
amd
product
candidates
generated
protease
engineering
platform
improved
functionality
potency
allow
sq
administration
recombinant
coagulation
factors
complement
inhibitors
high
activity
gene
therapy
constructs
less
frequently
dosed
intravitreal
therapeutics
statements
press
release
contains
statements
involve
substantial
risks
uncertainties
statements
include
statements
catalyst
plans
enroll
first
patient
phase
trial
marzaa
initiate
phase
trial
marzaa
fvii
deficiency
glanzmann
thrombasthenia
hemlibra
patients
potential
marzaa
effectively
therapeutically
treat
hemophilia
subcutaneously
superiority
cb
gene
therapy
candidates
company
collaboration
biogen
development
commercialization
pegylated
cb
potential
treatment
geographic
dry
macular
degeneration
actual
results
events
could
differ
materially
plans
intentions
expectations
projections
disclosed
statements
various
important
factors
could
cause
actual
results
events
differ
materially
including
limited
risk
trials
studies
may
delayed
result
factors
trials
may
satisfactory
outcomes
additional
human
trials
replicate
results
earlier
trials
potential
adverse
effects
may
arise
testing
use
marzaa
including
generation
neutralizing
antibodies
risk
costs
required
develop
manufacture
company
products
higher
anticipated
including
result
delays
development
manufacturing
resulting
factors
risk
biogen
terminate
catalyst
agreement
competition
risks
described
risk
factors
section
company
quarterly
report
filed
securities
exchange
commission
november
filings
securities
exchange
commission
company
assume
obligation
update
statements
except
required
law
contact
ana
kapor
catalyst
biosciences
investors
